Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $7.6 million.

  • Sangamo Therapeutics' Current Deferred Revenue rose 87622.74% to $7.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.6 million, marking a year-over-year increase of 87622.74%. This contributed to the annual value of $7.6 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Sangamo Therapeutics reported Current Deferred Revenue of $7.6 million as of Q3 2025, which was up 87622.74% from $7.6 million recorded in Q2 2025.
  • Sangamo Therapeutics' Current Deferred Revenue's 5-year high stood at $94.4 million during Q1 2021, with a 5-year trough of $774000.0 in Q3 2024.
  • For the 5-year period, Sangamo Therapeutics' Current Deferred Revenue averaged around $43.5 million, with its median value being $30.7 million (2022).
  • In the last 5 years, Sangamo Therapeutics' Current Deferred Revenue crashed by 9793.43% in 2023 and then skyrocketed by 87622.74% in 2025.
  • Sangamo Therapeutics' Current Deferred Revenue (Quarter) stood at $85.7 million in 2021, then crashed by 39.59% to $51.8 million in 2022, then crashed by 97.13% to $1.5 million in 2023, then soared by 408.82% to $7.6 million in 2024, then changed by 0.0% to $7.6 million in 2025.
  • Its Current Deferred Revenue stands at $7.6 million for Q3 2025, versus $7.6 million for Q2 2025 and $7.6 million for Q1 2025.